CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+9.19%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$709M
AUM Growth
+$709M
(-9.9%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-10.22%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
452
New
12
Increased
93
Reduced
281
Closed
40
Top Buys
| 1 |
NVIDIA
NVDA
|
$40.6M |
| 2 |
Apple
AAPL
|
$9.08M |
| 3 |
Applied Materials
AMAT
|
$5.39M |
| 4 |
Arista Networks
ANET
|
$5.26M |
| 5 |
Amphenol
APH
|
$5.14M |
Top Sells
| 1 |
Amgen
AMGN
|
$8.02M |
| 2 |
Adobe
ADBE
|
$7.95M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$7.6M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$6.84M |
| 5 |
Lam Research
LRCX
|
$5.23M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Healthcare | 22.25% |
| 3 | Consumer Discretionary | 12.69% |
| 4 | Communication Services | 10.44% |
| 5 | Consumer Staples | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
OmniAb
OABI
$227M
| $51.8K | 0.01% |
13,818
-8,503
| -38% | -$31.9K |
|
352
Terns Pharmaceuticals
TERN
$662M
| $51.8K | 0.01% |
7,600
-4,289
| -36% | -$29.2K |
|
353
Alector
ALEC
$262M
| $51.4K | 0.01% |
11,323
-7,080
| -38% | -$32.1K |
|
|
SLRN
354
DELISTED
ACELYRIN
SLRN
| $51.3K | 0.01% |
11,636
-7,082
| -38% | -$31.2K |
|
|
GRAL
355
GRAIL, Inc. Common Stock
GRAL
$1.14B
| $50.8K | 0.01% |
+3,302
| New | +$50.8K |
|
356
Voyager Therapeutics
VYGR
$199M
| $50.6K | 0.01% |
6,391
-4,013
| -39% | -$31.7K |
|
357
Taysha Gene Therapies
TSHA
$775M
| $49.2K | 0.01% |
21,971
-13,937
| -39% | -$31.2K |
|
358
Theravance Biopharma
TBPH
$697M
| $48.4K | 0.01% |
5,713
-3,870
| -40% | -$32.8K |
|
359
MaxCyte
MXCT
$143M
| $48.1K | 0.01% |
12,282
-7,602
| -38% | -$29.8K |
|
|
VERV
360
DELISTED
Verve Therapeutics
VERV
| $48.1K | 0.01% |
9,864
-6,207
| -39% | -$30.3K |
|
361
Precigen
PGEN
$1.42B
| $46.9K | 0.01% |
29,656
-18,173
| -38% | -$28.7K |
|
362
Pacific Biosciences
PACB
$384M
| $46.5K | 0.01% |
33,918
-19,530
| -37% | -$26.8K |
|
363
AC Immune
ACIU
$222M
| $46.4K | 0.01% |
11,621
-7,387
| -39% | -$29.5K |
|
364
Fulcrum Therapeutics
FULC
$347M
| $45.3K | 0.01% |
7,301
-4,615
| -39% | -$28.6K |
|
365
Editas Medicine
EDIT
$222M
| $45.1K | 0.01% |
9,661
-6,052
| -39% | -$28.3K |
|
366
Lyell Immunopharma
LYEL
$219M
| $43.4K | 0.01% |
29,951
-18,904
| -39% | -$27.4K |
|
367
Cabaletta Bio
CABA
$133M
| $42.4K | 0.01% |
5,671
-2,535
| -31% | -$19K |
|
368
Anavex Life Sciences
AVXL
$814M
| $42K | 0.01% |
9,943
-5,830
| -37% | -$24.6K |
|
369
Texas Roadhouse
TXRH
$11.4B
| $41.9K | 0.01% |
244
| – | – |
|
370
Phibro Animal Health
PAHC
$1.49B
| $40.1K | 0.01% |
2,390
-1,498
| -39% | -$25.1K |
|
371
Xeris Biopharma Holdings
XERS
$1.28B
| $39.2K | 0.01% |
17,418
-9,098
| -34% | -$20.5K |
|
372
Tourmaline Bio
TRML
$606M
| $38.7K | 0.01% |
3,012
-1,927
| -39% | -$24.8K |
|
373
Vanda Pharmaceuticals
VNDA
$278M
| $38.6K | 0.01% |
6,837
-4,208
| -38% | -$23.8K |
|
374
ALX Oncology
ALXO
$55.2M
| $36.9K | 0.01% |
6,122
-3,465
| -36% | -$20.9K |
|
375
Hyatt Hotels
H
$13.6B
| $36.5K | 0.01% |
240
| – | – |
|